Compare YUMC & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YUMC | ROIV |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 20.7B |
| IPO Year | 2016 | 2021 |
| Metric | YUMC | ROIV |
|---|---|---|
| Price | $49.19 | $28.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $27.56 |
| AVG Volume (30 Days) | 1.6M | ★ 4.5M |
| Earning Date | 04-29-2026 | 02-06-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ 7.73 | N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $11,797,000,000.00 | $29,053,000.00 |
| Revenue This Year | $9.42 | N/A |
| Revenue Next Year | $5.93 | $594.84 |
| P/E Ratio | $19.58 | ★ N/A |
| Revenue Growth | ★ 4.37 | N/A |
| 52 Week Low | $41.00 | $8.73 |
| 52 Week High | $58.39 | $30.33 |
| Indicator | YUMC | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 36.68 | 56.22 |
| Support Level | $43.02 | $26.94 |
| Resistance Level | $54.84 | $30.33 |
| Average True Range (ATR) | 1.28 | 0.95 |
| MACD | -0.40 | -0.12 |
| Stochastic Oscillator | 15.30 | 79.20 |
Yum China is the largest restaurant operator in China, with over 18,000 locations and USD 12 billion in systemwide sales as of 2025. It generates revenue mainly from its own restaurants and franchise fees. While KFC and Pizza Hut are its flagship brands, Yum China's portfolio also includes Little Sheep, Taco Bell, Huang Ji Huang, and Lavazza. As a trademark licensee of Yum Brands, Yum China pays 3% of KFC and Pizza Hut's systemwide sales to its former parent, from which it spun off in 2016. However, even before the separation, Yum China was granted substantial autonomy, giving its Chinese leadership decision-making authority over menu, supply chain, and marketing-an unusual practice for Western chains at the time.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.